ERBB2 and breast cancer: Given our recent findings involving the ADCP MOA for trastuzumab (20), we utilized our potentially novel models and approaches to interrogate the in vivo antitumor mechanism of pertuzumab in combination with trastuzumab against HER2-driven BC.